Development of novel topical tranexamic acid liposome formulations

被引:56
作者
Manosroi, A [1 ]
Podjanasoonthon, K [1 ]
Manosroi, J [1 ]
机构
[1] Chiang Mai Univ, Fac Pharm, Pharmaceut Cosmet Raw Mat & Nat Prod Res & Dev Ct, Inst Sci & Technol Res & Dev, Chiang Mai 50200, Thailand
关键词
tranexamic acids topical liposomes; hydrogenated soya phosphatidylcholine; cholesterol; dicetyl phosphate; stearylamine;
D O I
10.1016/S0378-5173(01)00980-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aims of this study were to develop novel liposome formulations for tranexamic acid (TA) from various lipid compositions {neutral (hydrogenated soya phosphatidylcholine and cholesterol), positive (stearylamine) or negative (dicetyl phosphate) charged lipids}, and to investigate the effects of concentrations of TA (5 and 10% in DI water) and charges on the physicochemical properties of liposomes. Liposomes were prepared by chloroform film method with sonication. The physical (appearance, pH, size, morphology) and chemical (drug encapsulation efficiency, transition temperature. enthalpy of transition) properties of liposomes were characterized. The TA contents were determined spectrophotometrically at 415 rim, following derivatization with 2,4,6-trinitrobenzosulfonic acid. The charged liposomes demonstrated better physical stability than the neutral liposomes. The percentages of TA entrapped in all liposome formulations varied between 13.2 and 15.6%. and were independent of TA concentrations and charges of liposomes. Charges affected the physical stability, pH and size of liposomes. The particle sizes of negative blank and positive liposomes (with and without the entrapped drug) were similar to 10 times larger than the negative liposome with the entrapped TA. The multilamellar 7:2:1 molar ratio of hydrogenated soy phosphatidylcholine/ cholesterol/dicetyl phosphate entrapped with 10% TA liposome (10% TA, -) was selected for further release Study, due to its high physical stability. small particle size and relatively high drug encapsulation efficiency. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:61 / 70
页数:10
相关论文
共 28 条
  • [1] ATMACA S, 1989, ACTA PHARM TURCICA, V31, P115
  • [2] TRANSFER OF LIPOSOMAL DRUG CARRIERS FROM THE BLOOD TO THE PERITONEAL-CAVITY OF NORMAL AND ASCITIC TUMOR-BEARING MICE
    BALLY, MB
    MASIN, D
    NAYAR, R
    CULLIS, PR
    MAYER, LD
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 34 (02) : 137 - 146
  • [3] BANGHAM AD, 1974, LIPOSOME TECHNOLOGY, V1, P37
  • [4] Benita S, 1984, J Microencapsul, V1, P203, DOI 10.3109/02652048409049359
  • [5] TRANEXAMIC ACID AS A MOUTHWASH IN ANTICOAGULANT-TREATED PATIENTS UNDERGOING ORAL-SURGERY - AN ALTERNATIVE METHOD TO DISCONTINUING ANTICOAGULANT-THERAPY
    BOREA, G
    MONTEBUGNOLI, L
    CAPUZZI, P
    MAGELLI, C
    [J]. ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 1993, 75 (01): : 29 - 31
  • [6] TOPICAL LIPOSOMAL LOCAL-ANESTHETICS - DESIGN, OPTIMIZATION AND EVALUATION OF FORMULATIONS
    FOLDVARI, M
    GESZTES, A
    MEZEI, M
    CARDINAL, L
    KOWALCZYK, I
    BEHL, M
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1993, 19 (19) : 2499 - 2517
  • [7] Liposome longevity and stability in circulation: Effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines
    Gabizon, A
    Chemla, M
    Tzemach, D
    Horowitz, AT
    Goren, D
    [J]. JOURNAL OF DRUG TARGETING, 1996, 3 (05) : 391 - 398
  • [8] GREGORIADIS G, 1988, LIPOSOME DRUG CARRIE
  • [9] JINCHUL K, 1997, PHARM DEV TECHNOL, V2, P275
  • [10] Kawakami S, 2001, J PHARM SCI, V90, P105, DOI 10.1002/1520-6017(200102)90:2<105::AID-JPS1>3.0.CO